Parkinson's disease (PD), the second most common neurodegenerative disorder globally, has long baffled scientists with its progressive nature and debilitating effects on motor function.
Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's disease and improved motor skills, the company reported on Thursday.
Researchers at UAB found blows to the head, like football players regularly experience, play a “significant” role in a person ...
The trial studied two doses of the drug, tavapadon, as a monotherapy in which patients showed a statistically significant ...
Parkinson's disease (PD), the second most common neurodegenerative disorder globally, has long baffled scientists with its ...
Phil Parkinson says Wrexham are in good shape as the League One leaders prepare to kick off a hectic week at Leyton Orient on ...
Parkinson's disease (PD), the second most common neurodegenerative disorder globally, has long baffled scientists with its progressive nature and ...
More than 10 million people worldwide are living with Parkinson's disease. India alone shares almost 10 per cent of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback